Neurosense Therapeutics Ltd (NRSN)vsBeiGene, Ltd. (ONC)
NRSN
Neurosense Therapeutics Ltd
$0.73
-1.48%
HEALTHCARE · Cap: $27.11M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
NRSN
Avoid16
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NRSN.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NRSN
NRSN has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : NRSN
The primary concerns for NRSN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
NRSN profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
NRSN carries more volatility with a beta of 1.56 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 16/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurosense Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm focused on developing groundbreaking therapies for neurodegenerative diseases, with a primary emphasis on Parkinson's disease. Through its proprietary development platform, the company is actively advancing several therapeutic candidates in critical clinical trials, highlighting its dedication to addressing significant unmet needs in neurology. Led by an experienced management team and supported by strategic partnerships, Neurosense is well-positioned to provide innovative treatment solutions that enhance patient quality of life while establishing a strong foothold in the biopharmaceutical industry.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?